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Background: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae 44 
(KPC-KP) has become one of the most important contemporary pathogens, 45 
especially in endemic areas. 46 
Aims: our aim was to provide practical suggestion for physicians dealing with the 47 
management of KPC-KP infections in critically ill patients, based on expert opinions. 48 
Sources: PubMed search for relevant publications related to the management of 49 
KPC-KP infections. 50 
Contents: a panel of experts developed a list of 12 questions to be addressed. In 51 
view of the current lack of high-level evidence, they were asked to provide answers 52 
based on their knowledge and experience in the field. The panel identified several 53 
key aspects to be addressed when dealing with KPC-KP in critically-ill patients 54 
(preventing colonization in the patient, preventing infection in the colonized patient 55 
and colonization of his/her contacts, reducing mortality in the infected patient by 56 
rapidly diagnosing the causative agent and promptly adopting the best therapeutic 57 
strategy) and provided related suggestions on the basis the available observational 58 
literature and the experience of panel members. 59 
Implications: Diagnostic technologies could speed-up the diagnosis of KPC-KP 60 
infections. Combination treatment should be preferred to monotherapy in the case 61 
of severe infections. For non-critically-ill patients without severe infections, results 62 
from randomized clinical trials are needed for ultimately weighing benefits and costs 63 
of using combinations rather than monotherapy. Multifaceted infection-control 64 
interventions are needed to decrease the rates of colonization and cross-65 
transmission of KPC-KP. 66 
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 67 
Introduction  68 
Management of infections caused by multidrug-resistant bacteria impacts 69 
considerably on health costs and becomes major modifier of health expenses in the 70 
ongoing antibiotic resistance crisis.1 Klebsiella pneumoniae carbapenemase (KPC)-71 
producing K. pneumoniae (KPC-KP), has become one of the most important 72 
contemporary pathogens, especially in endemic areas. 2-4 KPC-KP optimal treatment, 73 
however, is not known and there are currently no published recommendations for 74 
the management of infections by KPC-KP. Given the observational nature of the 75 
majority of studies on this topic, many of the recommendations listed in this 76 
manuscript arise from acquired experience of the invited panel members, and 77 
therefore represent expert opinion. 78 
Purpose and methods 79 
The purpose of this paper was to answer practical questions for physicians dealing 80 
with the treatment of KPC-KP infections in critically ill patients, in view of the 81 
fragmentation in the observational literature on this topic and the lack of 82 
randomized clinical trials.5 A panel of 11 experts developed a list of questions to be 83 
addressed in the paper; 12 questions were formulated after rounds of discussion 84 
between chairs (M. Bassetti, G. Poulakou, C. Viscoli, and H. Giamarellou) and panel 85 
members. In view of the lack of high-level evidence, panel members were asked to 86 
provide narrative answers on the basis of their knowledge and experience in the 87 
field. Finally, provided answers were reviewed and discussed by the panel, until a 88 
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consensus was reached. The final summary of selected questions and related 89 
answers is presented in table 1. 90 
 91 
Background information for provided answers 92 
1. How can the laboratory speed-up KPC-KP identification and susceptibility 93 
testing?  94 
Rapid methods for identification of strains producing KPC and other carbapenemases 95 
are important to ensure appropriate and early initiation of specific therapy, as well 96 
as the prompt implementation of the most appropriate infection control measures.6 97 
This is particularly relevant with KPC-KP or other types of carbapenemase-producing 98 
Enterobacteriaceae (CPE) infections, since commonly used regimens for empiric 99 
antimicrobial chemotherapy do not normally cover for MDR pathogens, except 100 
under specific circumstances (e.g., febrile neutropenia in a patient who is known to 101 
be colonized by KPC-KP).7  102 
Several new diagnostic technologies have recently become available to allow 103 
increased rapidity of microbiological diagnosis, including Matrix Assisted Laser 104 
Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS), rapid 105 
immunochromatography, rapid enzymatic assays (such as the Carba NP test), single-106 
cell automated time-lapse microscopy and molecular biology-based assays.8-10 These 107 
new technologies may be very useful to reduce the time for pathogen identification 108 
(ID) and antibiotic susceptibility test (AST) .  109 
MALDI-TOF MS has proven very successful in rapid bacterial identification 110 
from isolated colonies or monomicrobial blood cultures. MALDI-TOF MS can also be 111 
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used for rapid detection of some resistance determinants, such as beta-lactamases.11  112 
A mass spectrometric beta-lactamase (MSBL) assay represents a functional assay 113 
based on the direct monitoring of the enzymatic activity of the beta-lactamase and 114 
can be performed with bacterial cultures or directly from freshly tagged positive 115 
blood cultures, with results available after 1 - 4 hour incubation period.11 Both 116 
imipenem and meropenem can be used in these tests, with meropenem being 117 
somewhat more efficient.12 118 
This method, however, cannot identify the type of beta-lactamase. Recently, 119 
the identification of a 11,109-Da MS peak corresponding to a gene product of the 120 
blaKPC pKpQIL plasmid was found to be useful in rapid tracking KPC-producing 121 
strains.13  122 
Diagnostic platforms capable of rapid detection of blaKPC genes based on 123 
molecular biology techniques are currently available to target carbapenemase genes 124 
(e. g. Xpert Carba-R or Check-Direct CPE) in bacterial cultures or rectal swabs.14 125 
Others can identify blaKPC and other clinically relevant resistance genes directly from 126 
positive blood culture (e.g., FilmArray BC-ID or Verigene). Remarkably, in this 127 
case, the results are provided in about one hour compared to conventional 128 
microbiological methods that may take from 12 up to 72 hours.15 More recently, a 129 
polymerase chain reaction/electrospray ionization-mass spectrometry platform 130 
(IRIDICA) that detects more than 800 BSI-relevant pathogens and also blaKPC genes 131 
in approximately 6 hours was developed.16   132 
It should be noted that detection of resistance mechanisms by molecular biology is 133 
useful to rapidly predict potential resistance to some agents, but does not provide 134 
comprehensive information about the resistance phenotype of the infecting strain, 135 
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and conventional AST remains the cornerstone for selection of definitive treatment 136 
regimens and evaluation of adequate / inadequate antimicrobial chemotherapy.17 137 
However, the rapid detection of some resistance mechanism, and of KPC genes in 138 
particular (the presence of which means most of the time resistance to carbapenems 139 
and even multiresistance), can be very useful for an earlier revision of empiric 140 
regimens, which usually do not cover CPE.  141 
Availability of rapid diagnostic methods is associated with decreased length 142 
of stay, lower mortality and reduced costs in the long-term, provided that their 143 
implementation is feasible.6 Indeed, in some cases these techniques may represent 144 
an unaffordable expensive add-on to the routine diagnostic laboratory workflow, in 145 
terms of reagents and manpower cost, requiring a 24/7 schedule of sample 146 
processing. Furthermore, the information provided for AST is different from 147 
conventional minimum inhibitory concentration (MIC) values and must be suitably 148 
conveyed to the clinician to avoid confusion.  Overall, microbiology laboratories 149 
should have protocols for immediate notification of clinical teams whenever a CPE 150 
infection is identified 151 
 152 
2.  What is currently the best treatment for KPC-KP infections?  153 
A necessary premise is that only low-level evidence with a high risk of bias is 154 
available from observational studies regarding the optimal treatment for KPC-KP 155 
infections ,thus not allowing for definite conclusions. 5,18,19 In this light, the following 156 
statements are to be weighed cautiously, pending results of randomized clinical trials 157 
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(NCT01597973 and the AIDA study20 are ongoing or are have been recently 158 
completed, respectively).  159 
Since monotherapy appeared to be associated with higher mortality rates 160 
compared to combination therapy for the targeted treatment of KPC-KP in 161 
observational studies, the use of combined regimens should be preferred in patients 162 
with severe KPC-KP infections.19,21-25 Indeed, the positive impact of combination 163 
therapy on survival might be true only in patients with severe infections compared 164 
to less severe BSI and in non-bacteraemic intra-abdominal or UTIs, a fact which is 165 
also in line with the favourable survival effect of combinations recently observed 166 
only in patients with a high INCREMENT-CPE mortality score.23,25 In patients at lower 167 
risk of mortality, no clear survival benefit of combinations over monotherapy has 168 
been demonstrated. In these patients, a conservative combination approach might 169 
be used at the beginning, with the option of de-escalating to a simpler regimen in 170 
correlation with patient’s clinical conditions. However, the risk of inducing further 171 
resistance by the use of last-resort antibiotics is a non-negligible risk, and results 172 
from randomized clinical trials are needed for ultimately weighing benefits and cost 173 
of using combinations in patients with non-severe KPC-Kp infections. 174 
3. What is the role of carbapenems in the treatment  of KPC-KP infections?  175 
In combination treatment, meropenem may still be considered as an option 176 
for possibly enhancing bacterial killing, provided that: i) the MIC of meropenem is ≤ 177 
8mg/L and ii) a high-dose and prolonged infusion regimen is administered. With the 178 
limitations of the non-randomized design, a survival benefit by using meropenem-179 
based regimens has indeed been argued in many observational studies, with 180 
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published data mostly referring to meropenem-including combinations for treating 181 
KPC-KP bloodstream infections (BSI). In large multicentre studies conducted in Italy 182 
and Greece an increased survival by using combinations of meropenem was 183 
observed when KPC-KP exhibited MIC  ≤ 8 mg/L.23,24 Smaller cases series also 184 
suggested that increasing carbapenem dosage, use of prolonged infusion, and 185 
therapeutic drug monitoring (TDM) might be helpful for treating KPC-producing 186 
organisms with meropenem MICs up to 32-64 mg/L.26,27 However, clinical evidence 187 
supporting this possibility is preliminary,26,27 and the combination of two other 188 
agents showing in vitro activity against the given KPC-KP isolate should be 189 
considered as a reasonable alternative to carbapenem-including regimens. The 190 
administration of carbapenem-based regimens when facing meropenem MICs > 8 191 
mg/L might be considered for MICs up to 32-64 mg/L,  provided that TDM is 192 
available to monitor optimal drug exposure, in view of the risk of futility and 193 
perpetuation of resistance selection. 194 
Since carbapenem MICs are important for including or not meropenem in 195 
combination antimicrobial regimens against KPC-KP and other CPE, the accurate 196 
measurement of carbapenem MICs of KPC-KP is a clinically relevant issue. 197 
Unfortunately, automated systems and gradient diffusion tests (which are commonly 198 
used for AST in diagnostic microbiology) may be inaccurate for measurement of 199 
carbapenem MICs with KPC-KP and other CPE.28 Therefore, we recommend that 200 
carbapenem MICs of KPC-KP be determined using the reference broth microdilution 201 
methodology,29 covering meropenem concentrations up to at least 32-64 mg/L.  202 
 203 
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4. What molecules can be used to treat KPC-KP infections?  204 
A summary of the available drugs and their suggested dosage for treating 205 
KPC-KP infections is presented in table 2. Complete background information is 206 
available as Supplementary material S1.30-68 207 
 208 
5. What is the role of nebulized antibiotics in the treatment of ventilator-209 
associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT) by 210 
KPC-KP?  211 
Inadequate penetration of iv antibiotics that may be used against KPC-KP (including  212 
colistin, aminoglycosides, and tigecycline) to the epithelial lining fluid (ELF) have 213 
prompted the administration of aerosolized antibiotic therapy in patients with 214 
VAP.69 Clinical outcomes were usually non-comparable between clinical studies due 215 
to heterogeneity in regimens, indications (i.e., VAP, VAT, colonization), therapeutic 216 
approaches (iv antibiotic and/or nebulized) and different nebulizing devices used.70-217 
71 Data on KPC-producers is overall scarce. 218 
As maximal antibiotic delivery depends on the type of aerosol generators, 219 
novel drug-device combinations stand out as a promising delivery approach in 220 
critically ill patients. A randomized trial compared fixed combination of amikacin and 221 
fosfomycin (5:2 ratio) or placebo delivered via the investigational eFlow Inline 222 
System (PARI GmbH, Germany) as adjunctive treatment to standard iv antibiotics.72  223 
Distribution of multidrug-resistant (MDR) and extensively drug-resistant (XDR) 224 
isolates did not differ statistically between the two arms (10 and 5 KPC-KP were 225 
identified in target and control arms, respectively). Although clinical benefit was not 226 
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demonstrated, resistance selection was prevented and eradication of pathogens was 227 
higher in the nebulised arm.  228 
Several studies along with a rigorous meta-analysis performed by the European 229 
Society of Clinical Microbiology and Infectious diseases (ESCMID) critically ill patients 230 
study group (ESGCIP)73,74  argue for an unclear clinical benefit of inhaled antibiotic in 231 
VAP due to KPC-producers.69 A potential impact on  resistance, however, needs to be 232 
further investigated.69,75 Recently published guidelines recommend the add-on use 233 
of inhaled colistin in patients with VAP due to carbapenem-resistant pathogens that 234 
are susceptible only to colistin.76 The recommendation was based on a meta-analysis 235 
of four studies reporting that add-on nebulized colistin was associated with 236 
improved clinical cure. Non-responding VAP is another indication for add-on 237 
nebulized colistin.74  238 
 239 
6. Is prolonged infusion of beta-lactams preferable for KPC-KP?  240 
 Prolonged β-lactam infusions is intended to enhance the potency (i.e., fT>MIC) of 241 
these agents against pathogens with elevated MICs.77 Since KPC-KP is intrinsically 242 
resistant to carbapenems, the use of a pharmacodynamically optimized regimen that 243 
utilizes an increased dose and infusion time has been advocated as a technique to 244 
maximize in vivo exposures. 78,79 Enhancement of fT>MIC can be achieved using 245 
either continuous (total daily dose infused over a 24 hr period) or prolonged 246 
infusions (conventional 0.5 hr infusion prolonged up to 6 hours80,81). Carbapenem 247 
reduced stability at room temperature, requires frequent replacements of the 248 
antimicrobial at each dosing interval82,83 but provides pharmacodynamic 249 
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optimization and more flexibility for the nursing staff in the patient receiving 250 
polypharmacy and limited intravenous access. 251 
 252 
7. What about source control in patients with KPC-KP infections?  253 
The objective of source control includes the actions to control the foci of infection 254 
and to restore optimal function of the site of infection. Source control includes 255 
removal of implanted or tunnelled devices, open surgical or percutaneous drainage 256 
of infected fluids or abscesses, and surgical resection of infected tissues. Time from 257 
hypotension to implementation of source control has been found to be highly 258 
correlated with outcome. Therefore interventions to be undertaken for source 259 
control within the first 12 hours after the diagnosis of the septic syndrome, if 260 
feasible, should be considered.84  261 
Although source control is reported as a modifiable predictor of mortality in 262 
sepsis and septic shock 84, the data particularly from KPC-KP infections is scarce. In a 263 
two-match case control study including 99 patients in each arm comparing patients 264 
with KPC-KP and carbapenem susceptible K. pneumoniae, removal of focus of 265 
infection was independently associated with patient survival.85 In a prospective 266 
observational cohort study encompassing 53 patients with BSI caused by KPC-KP, 267 
prior surgery and therapeutic interventions targeting the removal of the site of 268 
infection were strongly correlated with survival.86 Similar conclusions were reported 269 
by Falcone et al in a retrospective analysis with 111 intensive care unit (ICU) patients 270 
with KPC-KP and septic shock in 21.6% cases. Source control process was 271 
accomplished in 95.2% of patients who survived in comparison to 31.2% who died. 272 
Cox regression analyses revealed that control of removable source of infection was 273 
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associated with favourable outcome (hazard ratio 0.14, Cl 95%, p<0.001).87 In a 274 
retrospective study including 48 BSI due to KPC-KP, adjunctive source control 275 
procedures were associated with clinical response at day 7 (odds ratio 12.2, Cl 276 
95%1.4-110, p=0.025).88  277 
 278 
8. What is the optimal duration of treatment for KPC-KP infections?  279 
Optimal treatment duration for KPC-KP infections is unclear. In retrospective studies 280 
a mean duration of two weeks of treatment was reported.89  In VAP, robust data 281 
supports a reduced 8-day antibiotics course in patients receiving appropriate initial 282 
empirical therapy.90-92 This strategy was associated with significantly more antibiotic-283 
free days without negative impact on mortality and reduced resistance selection. 284 
Higher relapse rates in patients with non-fermenting Gram-negative bacilli were 285 
initially reported suggesting longer treatments when these pathogens were 286 
responsible for VAP.90 An updated meta-analysis of VAP caused by non-fermenters, 287 
however, supported a reduced length of treatment (e.g., 7 days) that is currently 288 
recommended by guidelines.76   289 
As far as bacteremia is concerned, the evidence is even less clear. Havey et al 290 
in a large systematic review and meta-analysis encompassing 24 trials, showed that 291 
patients receiving short treatment (5-7 days) versus those receiving long treatment 292 
(7-21 days) for non-Staphylococcus aureus bacteremias had no significant differences 293 
in mortality, microbiological eradication and clinical cure. Randomized-controlled 294 
trials to assess the optimal duration of bacteremia in the context of MDR and KPC-295 
producers are awaited and may provide baseline evidence that long treatments may 296 
not be necessary.93 In another meta-analysis, antibiotic algorithms guided by 297 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
procalcitonin levels were found to safely guide reduced treatment duration without 298 
any negative impact on survival.94 These findings, suggest that a holistic approach 299 
combining adequate sterilization of septic foci (microbiological eradication), 300 
optimization of antibiotic exposure in critically ill patients, and the usage of 301 
biomarkers enabling monitoring of the effectiveness of administered treatment may 302 
allow for shorter treatment durations even in the presence KPC-producers.  303 
 304 
9. Can KPC-KP infections be prevented? And how? 305 
The ESCMID recently released guidelines aimed to decrease the transmission of MDR 306 
Gram-negative pathogens.95,96 The most robust measure to prevent inter-patient 307 
transmission of KPC-KP appeared to be hand hygiene.97 In a study showing 30% 308 
reduction of KPC-KP transmission rate, this achievement was possible in a 8 to 12 309 
week timeframe with active surveillance, contact precautions and isolation or 310 
cohorting, but only if at least 60% compliance with hand- hygiene compliance was 311 
reached.  312 
Additional measures include minimizing use of invasive devices, promotion of 313 
antimicrobial stewardship, a standardized approach for active surveillance of at risk 314 
populations, and protocols for discontinuation of carrier status.   315 
Routine rectal swab surveillance of KPC-KP contacts is an important measure 316 
to enhance identification and isolation of carriers, but should not be used as an 317 
single infection-control measure to prevent KPC-KP dissemination. 95,98-100 In this 318 
regard, multifaceted interventions are more likely to be successful. For example, the 319 
combination of daily baths with 2% chlorhexidine impregnated wipes, point-320 
prevalence surveillance with swabs, isolation of colonized/infected patients, 321 
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cohorting of medical personnel, enhanced environmental surveillance and repetitive 322 
educational campaigns successfully controlled the further horizontal spread of a 323 
monoclonal KPC-KP strain.101 In another study, transmission through contaminated 324 
sinks has been suggested as the major responsible for a long-term, low-frequency 325 
hospital outbreak of KPC-KP infections, further confirming the need for accurate 326 
environmental surveillance and disinfection.102 In a study from Israel, a significant 327 
decline of the nosocomial CPE acquisition was achieved with a multiple step 328 
strategy, including ward-based mandatory guidelines for carrier isolation, patient 329 
and staff cohorting, active surveillance and new rules for microbiology identification, 330 
direct officer visits at healthcare facilities and networking.103  331 
An important factor to consider is the presence of super-spreaders (i.e., 332 
those carriers who more easily spread KPC-KP in their immediate environment94). 333 
Super-spreaders are characterized by high rectal CPE concentrations and are more 334 
frequently admitted for respiratory disease.104 This effect has similarities with other 335 
so called “enteropathogenetic syndromes” such as Clostridium difficile colitis and 336 
candidemia, at least by the means of exogenous colonization.104,105 In a multicentre 337 
US study, KPC-KP clearance was attributed to a reduction in the usage of urinary 338 
catheters, a factor that should be considered in the implementation of a bundle 339 
procedure.106  340 
 341 
10. Who among KPC-KP colonized patients is at increased risk of developing KPC-KP 342 
infections? 343 
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Many studies have focused on the role of KPC-KP colonization in the development of 344 
infection in order to guide the selection of appropriate interventions and 345 
administration of early appropriate treatment. 346 
In a retrospective study involving five large Italian hospitals, bowel 347 
colonization by KPC-KP held a major role in predicting transition from colonization to 348 
infection.107 The overall number of colonized sites represented the most important 349 
risk factor for KPC-KP BSI development among rectal carriers in a prospective 350 
multicentre study.108,109 Other risk factors for KPC-KP BSI included ICU admission, 351 
abdominal invasive procedures, chemotherapy or radiation therapy, and previous 352 
BSI.108,110 In a study including patients undergoing open heart surgery, colonization 353 
was the most important risk factor for KPC-KP infection.111 In a prospective cohort 354 
study of adult patients undergoing liver transplant (LT), KPC-KP infection rates 355 
among patients non-colonized, colonized at LT, and colonized after LT were 2%, 356 
18.2% and 46.7%, respectively.108 In settings where colonization with KPC-KP is 357 
common among critically ill patients, antibiotic stewardship programs should be 358 
undertaken to optimize antimicrobial use, as shown by a study demonstrating high 359 
risk of KPC-KP VAP in colonized patients receiving prolonged antimicrobial 360 
therapy.112  361 
Risk analysis of high mortality rates (64%) among oncohaematological 362 
patients undergoing allogenic transplant, highlighted the presence of pre-transplant 363 
KPC-KP infection and the absence of active first-line antibiotic treatment, identifying 364 
the need for targeted interventions.113 A subsequent report illustrated the safety 365 
and efficacy of allogenic HSCT in patients colonized by the KPC-KP using the “Turin 366 
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bundle”: avoidance of levofloxacin prophylaxis, treatment with gentamicin per os in 367 
the best window of opportunity pre-transplant, administration of tigecycline and 368 
piperacillin/tazobactam as empiric treatment of febrile neutropenia, and 369 
administration of combination regimens (e.g., colistin plus tigecycline plus 370 
meropenem) in patients with severe sepsis or septic shock.114 In another study, the 371 
cumulative incidence of KPC-KP BSI and septic shock at one year after 372 
haematopoietic stem cell transplantation was significantly reduced from 62.5% to 373 
16.6% after the introduction of systematic screening with rectal swabs, contact 374 
precautions, and early targeted treatment in neutropenic patients with fever, with at 375 
least two antibiotics.115 Finally, a multifaceted infection control program was able to 376 
reduce both BSI due to CPE and CPE colonization, whereas monthly incidence of CPE 377 
carriage was predictive of BSI.116  378 
 379 
11. Is decolonization a useful strategy in KPC-KP colonised patients? 380 
Studies deploying oral decolonization strategies as a mean to eradicate gut 381 
carriage of KPC-KP have produced conflicting results and only one reported a survival 382 
benefit (Table 3).117-123 With regard to the use of oral gentamicin for decolonization 383 
purposes, an indiscriminate use should be avoided. Indeed, this strategy has a high 384 
risk of failure and also cannot be separated from the risk of selecting gentamicin 385 
resistance (and thus of losing one of the last - if not the last - therapeutic 386 
options).120,123 It should therefore be reserved for very selected special conditions 387 
(e.g., very high risk of developing infection because of severe neutropenia or 388 
recurrent KPC-KP infections) on a patient-by-patients basis.123  389 
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12. What is new in KPC-KP treatment options?  390 
A handful of new compounds, expected to address the therapeutic problem of KPC-391 
KP in the near future are summarized in Table 4 (reporting molecules in Phase 3 of 392 
clinical development).124-137  393 
Conclusions 394 
The optimal management of KPC-KP infections in critically ill patients relies on 395 
concerted multidisciplinary approach. On a case-by-case basis, efforts should indeed 396 
be directed towards preventing colonization, infection, or mortality. Each 397 
intervention has its peculiar issues to be addressed (preventing colonization in the 398 
patient, preventing infection in the colonized patient and colonization of his/her 399 
contacts, reducing mortality in the infected patient by rapidly diagnosing the 400 
causative agent and promptly adopting the best therapeutic strategy), but all are 401 
crucial to ultimately curtail the high mortality of KPC-KP infections. High-level 402 
evidence is urgently needed to firmly guide physicians through all these steps. 403 
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 954 
 955 
Table 1. Clinical question defined by the panel and related answers based on 956 
expert opinion 957 
Question 1 How can the laboratory speed-up KPC-KP identification and susceptibility 
testing? 
 
Diagnostic technologies could speed-up the diagnosis of KPC-KP 
infections and potentially improve patients’ outcome. However, whether 
or not they should be introduced into the laboratory workflow remain a 
choice to be carefully balanced locally, according to the available 
resources and personnel in every single hospital. 
 
Question 2 What is currently the best treatment for KPC-KP infections? 
 
Combination treatment should be preferred to treat KPC-KP infections 
compared to monotherapy in the case of severe infections and for 
critically ill patients. For non-critically-ill patients without severe 
infections, results from randomized clinical trials are needed for 
ultimately weighing the related benefits and costs, also in terms of  
induction of resistance. 
 
Question 3 What is the role of carbapenems in the treatment of KPC-KP infections? 
 
Administration of high-dose (e.g., 2 grams q 8 hours), prolonged infusion 
meropenem could be beneficial in KPC-KP infections if MIC is ≤ 8 mg/L. 
For MIC up to 32-64 mg/L, meropenem administration should  be 
considered if TDM is available to monitor optimal drug exposure. 
 
Question 4 What molecules can be used in the treatment of KPC-KP infections? 
 
Various molecules can be used in combination treatment against KPC-KP, 
including aminoglycosides, polymyxins, tigecycline,  fosfomycin, and 
carbapenems in selected cases (see table 2 for details). 
 
Question 5 What is the role of nebulized antibiotics in the treatment of ventilator-
associated pneumonia (VAP) and ventilator-associated tracheobronchitis 
(VAT) by KPC-KP?  
 
The use of nebulised antibiotics could be useful in selected clinical 
scenario, especially when there is lung involvement  (e.g., use of inhaled 
colistin in VAP due to carbapenem-resistant pathogens). 
  
Question 6 Is prolonged infusion of beta-lactams preferable for KPC-KP? 
To achieve pharmacodynamic optimization in KPC-directed regimens, 
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prolonged infusion should be combined with high-dose regimens. To 
achieve pharmacodynamic optimization in KPC-directed regimens, 
prolonged infusion should be combined with high-dose regimens. 
 
Question 7 What about source control in patients with KPC-KP infections? 
 
Although data among patients with KPC-KP infections is limited, source 
control in this population has been associated with favourable outcomes 
and should be performed promptly whenever possible. 
 
Question 8 What is the optimal duration of treatment for KPC-KP infections? 
 
Treatment duration for KPC-KP infections should vary according to the 
source of the infection. Factors such as achievement of microbiological 
eradication, use of biomarkers and optimization of antibiotic exposure 
could be used to reduce treatment duration 
 
Question 9 Can KPC-KP infections be prevented? And how? 
 
Multifaceted infection control components are needed to decrease the 
rates of colonization and cross transmission of KPC-Kp. 
 
Question 10 
 
 
 
 
 
 
 
Who among KPC-KP colonized patients is at increased risk of developing 
KPC-KP infections? 
 
Proper management of colonized patients, including surveillance and 
antimicrobial stewardship programs, are essential and contribute to 
ensure an early  and appropriate treatment in patients with signs of 
infection. 
Question 11 Is decolonization a useful strategy in KPC-KP colonised patients? 
Decolonization of KPC-Kp carriers is currently not supported by large 
studies and may be considered only in selected cases. 
 
Question 12 What’s new in KPC-KP treatment options? 
 
Novel compounds targeting KPC-KP are under investigation and appear 
promising for their treatment, including meropenem-vaborbactam, 
imipenem-relebactam, plazomicin, cefiderocol, and eravacycline. Among 
these, meropenem/vaborbactam and plazomicin have already 
demonstrated some interesting and favourable results in treating KPC-KP 
infections. 
 
KPC-KP, Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae. 958 
 959 
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Table 2. Antimicrobial agents Against Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-KP). 961 
Drug Loading dose 
 
Daily dose for normal  
renal function 
Comments 
Polymyxins 
[ref. 30-41]  
 
Colistina 
 
 
 
 
 
Polymyxin Bb 
 
 
 
 
 
9 million IU  
 
 
 
 
 
Not required 
 
 
 
4.5 million IU IV q 12h.  
Intrathecal/intraventricular: 
125.000-250.000 IU 
Inhaled: 1 to 3 million IU q 
8h  
 
7500–12500 IU/Kg q 12 h q 
12 h  
Intrathecal/intraventricular: 
50000 IU q 24 h 
 
 
 
 
For infections caused by organisms with MIC >0.5 mg/L, it is advisable to 
use colistin as part of combination therapy. For dosage adjustment in 
patients with renal failure refer to nation R et al.29 
 
 
 
No dose adjustment for renal failure. 
 
 
Aminoglycosides 
[ref. 42-45] 
 
Gentamicin 
 
 
 
 
Amikacin          
 
 
 
Not required when 
administered in 
pulse dosing 
schemes 
 
Not required when 
administered in 
 
 
 
5 to 7 mg/kg infused over 1 
h 
 
 
 
15 to 20 mg/kg infused over 
1 h  
 
 
 
Aminoglycosides can be useful as part of combination regimens for 
treating KPC-KP infections, especially if colistin resistance is 
documented. Pulse dosing is preferable to multiple daily doses; desired 
peak serum levels are about 10 times the MIC of the organism. Adjust 
doses according to Hartford nomogram.43  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
pulse dosing 
schemes 
 
 
 
Tigecycline  
[ref. 21,22,46-52] 
 100-200 mg 
  
50-100 mg q 12 h IV  
 
For BSIs or pneumonia or when tigecycline MIC > 0.5 mg/L, higher doses 
are recommended (loading dose, 200 mg followed by 100 mg q 12 h), 
preferably in combination with another agent. Not to be used in urinary 
tract infections, no concentrations in urine.  
 
Fosfomycin 
[ref. 38,53-58] 
Not required 18 to 24 g IV in 3 to 4 doses Fosfomycin could be used in combination treatment for KPC-KP 
infections administered as 6 to 8g every 8 hours. Resistance can occur 
during treatment and should be monitored. The potential of fosfomycin 
to select resistant mutants precludes its use as a single agent. 
 
Ceftazidime/ 
avibactam 
[ref. 59-63] 
Not required 2.5g q 8 h IV infused over 2 
h 
Approved for complicated urinary tract and intra-abdominal infections; 
active in vitro against Enterobacteriaceae producing ESBLs, AmpC, KPC 
and OXA-48. Clinical experience for carbapenem-resistant 
Enterobacteriaceae  is currently limited to case series.56-59  
Despite concerns of resistance selection raised by a few reports that 
might support the used of ceftazidime/avibactam in combination with 
other agents for treating KPC-KP infections, whether it should be 
ultimately used alone or combined remain unclear, and requires further 
dedicated investigation. 
 
Meropenem 
[ref. 23-29,64-68] 
 
 
1-2 g 
 
 
 
2 g q 8 h IV infused over 3-6 
h 
 
 
Meropenem should be used in combination with another active agent; 
the probability of response is higher when meropenem MIC ≤ 8 mg/L. 
Salvage therapy with association of two carbapenems, e.g. ertapenem 
plus either meropenem or doripenem can be considered when other 
options are not suitable or available. 
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a. 1 mg of colistin base activity is contained in 2.4 mg colistimethate which is equivalent to 30,000 IU. 962 
b. 1 mg of polymyxin B is equivalent to 10,000 IU  963 
  964 
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 965 
Table 3. Summary of studies reporting  decolonisation strategies as a means of eradicating KPC-KP carriage 966 
Study Design-Population Intervention Main outcome  Comment 
Zuckerman T et al, 
2011 [ref. 117] 
Pilot study in haemato-
oncology and Bone Marrow 
Transplant unit (15 patients) 
Goal: To eradicate carbapenem 
resistant Klebsiella pneumoniae 
(CRKP) from rectal carriage 
Oral gentamicin at a dose of 80 mg 
q.i.d. was  administered to all identified 
carriers until eradication [median 
duration of 27 days (range: 7–90)]. 
Eradication rate achieved was 66% (10/15) 
and lasted for a median of 9 months (range: 
2–10); discontinuation of persistent 
bacteremia occurred in 62.5% (5/8) and 
nosocomial spread of CRKP carrier state 
ceased 
No gentamicin resistance was detected in blood 
isolates during oral gentamicin treatment. 
Administration of intensive chemotherapy and SCT 
was feasible. 
Saidel-Odes L, et al, 
2012 [ref. 118] 
A randomized, double-blind, 
placebo-controlled trial in a 
1,000-bed tertiary-care 
university hospital. 
 
Forty adults with CRKP-positive rectal 
swab cultures. 
The SDD arm received oral gentamicin 
and polymyxin E 
gel (0.5 g 4 times per day) and oral 
solutions of gentamicin (80 mg 4 times 
per day) and polymyxin E (1X 10
6
 units 
4 times per day for 7 days). 
Positive for CRKP rectal cultures were 
significantly reduced by 2 weeks [16.1% in 
the placebo arm and 61.1% in the SDD arm 
were negative (odds ratio, 0.13; 95% 
confidence interval, 0.02–0.74; P <0 .0016)]. 
Difference between the 2 arms was still 
maintained 
at 6 weeks (33.3% vs 58.5%). 
There was no evidence of an increase in 
either gentamicin or polymyxin E MIC, 
among CRKP isolates. 
SDD was effective as decolonization strategy for 
selected patients colonized with CRKP, such as 
transplant recipients or immunocompromised 
patients pending chemotherapy and candidates for 
major intestinal or oropharyngeal surgery. 
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Lübbert C et al, 2015 
[ref. 119] 
A single centre outbreak of 
KPC-2 , affecting 90 patients 
hospitalized over 28 months.  
Retrospective analysis, of 
patients who received selective 
digestive decontamination 
(SDD) compared with the 
remaining patients harbouring 
KPC-2-KP. 
14 consecutive patients were treated 
with a short course (7days) of SDD 
regimen consisting of colistin (1 million 
units q.i.d.) and gentamicin (80 mg 
q.i.d.) as oral solutions, and colistin 
/gentamicin gel (0.5g) to the oral 
cavity. 
Decolonisation of KPC-2-KP was achieved in 
6/14 patients (43%) after a mean of 21days 
(range12–40 days), but was also observed in 
23/76 (30%). 
 Secondary resistance to colistin(by 19%) and 
gentamicin (by 45%) was observed in SDD 
group but not in the comparative group. 
of thenon-SDD controls (P = 0.102). 
 
The SDD approach was not sufficiently effective for 
decolonization and was associated with high rates of 
resistance in subsequent cultures. 
Tascini C, et al, 2014 
[ref. 120] 
A pilot non-blinded, 
prospective study in three 
Italian hospitals 
to assess the feasibility of 
administering oral gentamicin 
for KPC-Kp 
gut decontamination. Patients 
enrolled had gut colonization 
by gentamicin-susceptible 
KPC-Kp  and were candidates 
for planned surgery, major 
medical intervention, or need 
for patient transfer. 
Oral gentamicin, 80 mg four times 
daily, was administered to 50 
consecutive patients over an 8 month 
period. 
A separate analysis was performed 
with the 23 patients receiving oral 
gentamicin alone and with the 27 
patients who received Concomitant 
Systemic Antibiotic Treatment (CSAT). 
Oral gentamicin was given for a median 
of 16 days (interquartile range, 10 to 
27 days). 
 
KPC-Kp infections were documented in 5/34 
(15%) successfully decontaminated patients 
compared to 12/16 (73%) persistent carriers 
(P<0.001).  
The decontamination rate was 96% (22/23) 
in patients receiving oral gentamicin only, 
compared to 44% (12/27) of those treated 
with oral gentamicin and CSAT (P<0.001).  
Gentamicin-resistant KPC-Kp strains were 
isolated from stools of 4/16 persistent 
carriers 
useful for gut decontamination and 
prevention of infection due to KPC-Kp, especially in 
patients not receiving CSAT. 
No difference in overall mortality was observed 
between decontaminated 
and persistently colonized patients. 
Oren I, et al, 2013 
[ref. 121] 
A semi-randomized, 
prospective, controlled trial 
was conducted to eradicate 
152 patients were included; 50 patients 
received 1 of the 3 drug regimens: 
gentamicin, 26; colistin, 16; both drugs, 
Eradication rates in the 3 treatment groups 
were 42%, 50%, and 37.5%, respectively, 
each significantly higher than the 7% 
Administration of oral nonabsorbable antibiotics was 
an effective and safe strategy for eradication of CRE 
colonization and, thereby, may reduce patient-to-
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CRE colonization  using oral 
nonabsorbable antibiotics.  
8, followed for a median duration of 33 
days and 102 were followed for 
spontaneous eradication for a median 
duration of 140 days (controls). 
Antibiotic selection was based on 
isolate’s in vitro susceptibility. 
spontaneous eradication rate in the control 
group (P < .001, P < .001, and P = .004, 
respectively) with no difference between the 
regimens. No significant adverse effects were 
observed. 
patient transmission and incidence of clinical 
infection. A trend towards 
lower mortality  among patients who succeeded 
eradication on treatment (2/22, 9%), compared with 
those who failed 
eradication on treatment (9/28, 32%) was observed 
(p=0.052) 
Tascini C et al, 2015 
[ref. 122] 
A 1:1 case control study 
exploring prevention of KPC-Kp 
gut 
colonization in patients that 
undergo 
hepatectomy with oral 
gentamicin in an endemic 
setting 
All 31 consecutive patients 
who underwent liver resections in the 
last year treated orally with 
gentamicin; 
controls were 31 patients who 
underwent surgery in the same ward in 
the previous year without gentamicin 
prophylaxis. 
The overall gut  colonization rate in the 
intervention group 
was 3 % (1/31) versus 29 % (9/31) in the 
control group (p = 0.016). 
The only KPC-Kp strain isolated in the 
gentamicin-treated group retained 
susceptibility  
to gentamicin 
Oral administration of gentamicin might be effective 
to avoid KPC-Kp 
gut colonization without adverse events. 
Machuca I et al, 2016 
[ref.123] 
A retrospective cohort study of 
patients colonized by KPCKP  
in two hospitals during an 
outbreak with colistin-resistant 
KPCKP strain, exploring 
whether 
decolonization 
therapy (DT) with 
aminoglycosides had a 
protective effect in selected 
77 patients at high risk [(a) neutropenia 
(b) major surgery; (c) multiple 
comorbidities], with rectal colonization 
by colistin-resistant KPCKP were 
followed for 180 days. 
Oral aminoglycosides (gentamicin or 
combination of 
neomycin/streptomycin)  were 
administered in 44 patients. 
 
At 180 days of follow-up, decolonization was 
associated with a lower risk of mortality in 
multivariate analyses (HR 0.18; 95% CI 0.06–
0.55) and a lower risk of KPCKP infections 
(HR 0.14; 95% CI 0.02–0.83) and increased 
microbiological success (HR 4.06; 95%CI 
1.06–15.6). Beneficial effects were more 
favorable with gentamicin.  
Intestinal decolonization with aminoglycosides is 
associated with a reduction in crude mortality and 
KPCKP infections.  
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Table 4. New antimicrobials with potential activity against KPC producing Enterobacteriaceae  983 
Antibiotic Antibiotic class Resistant phenotypes Status of development Company Comments 
Ceftazidime/ 
avibactam 
β- lactam/β-lactam 
inhibitor 
Activity against 
Enterobacteriaceae 
producing KPCs, ESBLs, 
OXA, AmpC enzymes.  
No activity against Class B 
beta-lactamases (MBL, 
VIM, NDM).  
Avibactam offers no 
enhanced activity against 
Pseudomonas aeruginosa 
and Acinetobacter 
baumannii 
-Non-inferiority versus 
imipenem and meropenem 
in Phase 2 clinical trials for 
the treatment of cUTIs and 
cIAIs respectively  
-Licensed in US, and EU for  
cUTIs and cIAIs 
-Awaiting results of Phase 3 
trial in VAP 
Phase 1 study on PKs of 
critically ill patients 
planned 
 
US: Allergan Inc. 
EU: Astra Zeneca 
Ceftazidime-avibactam was recently licensed 
for the treatment of cUTIs and cIAIs in US and 
Europe.124,125 The registration trials, however, 
did not include CRE isolates.  
Ceftaroline/ 
avibactam 
β- lactam/β-lactam 
inhibitor 
ESBL- and KPC-producing 
Enterobacteriaceae. 
Avibactam effectively 
inhibits Ambler class A 
(e.g., ESBL and KPC), C 
(AmpC), and some D (OXA-
like) enzymes. 
No activity against A. 
baumannii or P. 
aeruginosa 
No activity against Class B 
enzymes (MBL) 
 
-Completed phase 1 trials 
and one phase 2 trial in 
cUTIs 
-Completed a Phase 2 trial 
in cUTIs versus doripenem, 
and three Phase 1 trials 
awaiting results 
Forest Laboratories Ceftaroline–avibactam has a promising in vitro 
spectrum; results from clinical trials are 
pending.124,126  
Imipenem/ carbapenem/ β- Class A and C β- Completed phase 2 trial in Merck Relebactam is under investigation in 
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relebactam lactamase inhibitor 
(diazabicyclooctane)  
lactamases, porin 
mutations, Class D (OXA-
48 not consistently) 
No activity against MBL 
cUTI, currently in Phase 3 
trials versus colistin against 
imipenem resistant 
pathogens and versus 
piperacillin tazobactam in 
bacterial pneumonia 
 
combination with imipenem/cilastatin with 
Phase 3 trials underway versus colistin for 
imipenem-resistant pathogens and versus 
piperacillin/tazobactam in bacterial 
pneumonia.124,63,127 
 
Meropenem/ 
vaborbactam 
(RPX 7009) 
carbapenem/boronic 
acid-based β-
lactamase inhibitor  
Class A β-lactamases (KPC 
and most AmpC)  
No activity against MBL 
and Class D OXA-48 
-Completed Phase 3 trial 
in cUTI, 
-Ongoing Phase 3 trial in 
various infections caused 
by carbapenem resistant 
bacteria,  
-Planned Phase 3 trial in 
VAP 
 
The Medicines 
company 
The boronic-based beta-lactamase inhibitor 
vaborbactam combined with meropenem 
(Carbavance) is currently in Phase 3 trials.63,128  
Plazomicin New aminoglycoside 
(neoglycoside) 
Various Gram-positive and 
Gram-negative organisms 
Not active against bacteria 
harboring ribosomal 
methyltransferases 
(mostly NDM-1 strains) 
Completed two phase 3 
trials (cUTIs and serious 
infections by CRE) 
Submission for FDA 
approval  in 2017 and EMA 
in 2018 
Achaogen A new parenteral hemisynthetic 
aminoglycoside with favourable 
pharmacokinetics and safety profile, 
plazomicin, holds also promise against KPC-
producers.63,124 Its efficacy against 
carbapenem-producing bacteria has been 
recently demonstrated in serious infections 
including BSI, HAP/VAP, and cUTI.129,130 
 
Cefiderocol, 
S-649266 
Siderophore 
cephalosporin 
ESBL, Class A (KPC) and 
Class B (NDM-1)  
carbapenemases and OXA-
type enzymes, broad range 
of pathogens including A.  
Completed phase 2 trial in 
UTI, currently in Phase 3 
trials for severe infections 
by CRE. 
Phase 3 in nosocomial 
Shionogi Cefiderocol (formerly S-649266) is a promising 
siderophore cephalosporin, showing high 
activity against carbapenem-resistant Gram-
negative bacteria, and it is currently in Phase 3 
trial.63,124,131  
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baumannii, P. aeruginosa, 
S. maltophilia, and 
Enterobacteriaceae (CRE) 
 
pneumonia scheduled  
Eravacycline Tetracycline ESBL, KPC, NDM and OXA 
producing Escherichia coli 
and K. pneumoniae. 
Active against A. 
baumannii and  S. 
maltophilia. 
Not active against P. 
aeruginosa 
Completed phase 2 trials in 
cIAI, 
Currently in Phase 3 trials 
in cIAI (versus meropenem) 
and in cUTI (versus 
ertapenem/levofloxacin) 
Tetraphase 
Pharmaceuticals 
Inc 
Eravacycline is a novel fluorocycline with in 
vitro activity against Enterobacteriaceae 
harbouring a variety of resistance genes 
(ESBLs or carbapenemases), potential activity 
against A. baumannii, but not against P. 
aeruginosa.63,124,,132,133 Compared to 
tigecycline, it is more potent in vitro two- to 
eightfold against Gram-negative bacilli and 
exhibits 1-fold higher Cmax and AUC0-12 in ELF. 
134,135 Non-inferiority was demonstrated in a 
Phase 3 study evaluating the safety and 
efficacy of eravacycline versus ertapenem in 
cIAI,136 but not in the trial of cUTIs compared 
to levofloxacin.137     
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